Open Access
CC BY 4.0 · J Neurol Surg B Skull Base 2018; 79(S 01): S1-S188
DOI: 10.1055/s-0038-1633448
Oral Presentations

Expression of Programmed Cell Death-Ligand 1 in Esthesioneuroblastoma

Authors

  • Nyall R. London

    1   Johns Hopkins, Baltimore, Maryland, United States

  • Justin Bishop

    2   University of Texas − Southwestern, Dallas, Texas, United States

  • Lisa Rooper

    1   Johns Hopkins, Baltimore, Maryland, United States

  • Janis Taube

    1   Johns Hopkins, Baltimore, Maryland, United States

  • Masaru Ishii

    1   Johns Hopkins, Baltimore, Maryland, United States

  • Gary Gallia

    1   Johns Hopkins, Baltimore, Maryland, United States
Further Information
Also available at
 
 

Background Programmed death-ligand 1 (PD-L1) is a transmembrane glycoprotein which interacts with the receptor programmed death 1 (PD-1) to suppress T-cell signaling, increase tolerance to self-antigens, and promote tumor immune evasion. There has been significant recent interest in the chemotherapeutic use of immune checkpoint inhibitors including the PD-L1/PD-1 pathway due to significant efficacy observed in melanoma and non-small cell lung cancer. These inhibitors are believed to act through reinvigoration of tumor-associated CD8+ T cells. Preclinical studies with glioma cells in mice treated with anti-PD-1 treatment combined with radiation have shown promise and numerous clinical trials are actively investigating PD-L1/PD-1 blockade in malignant glioma and recurrent glioblastoma. Despite these advances, the expression of the PD-L1/PD-1 pathway in esthesioneuroblastoma (ENB) has yet to be investigated. The goal of this study was to determine the expression pattern of PD-L1 and PD-1 in ENB and to determine the presence of CD8+ cells in PD-L1 expressing tumors.

Methods Immunohistochemical analysis for expression of PD-L1 was performed on a total of 10 available samples of ENB. Tumors expressing PD-L1 underwent further immunohistochemistry analysis to determine the expression of PD-1 as well as the presence of tumor-associated CD8+ cells. A review of clinical records from these 10 samples was performed.

Results Three of the ten ENB specimens demonstrated significant positive PD-L1 expression. Two of the PD-L1-positive tumors were available for additional immunohistochemical analysis. Both specimens demonstrated the presence of CD8+ cells and the highest PD-L1 expressing specimen demonstrated 75% coexpression of PD-1. Further analysis of PD-L1 expressing ENB did not demonstrate a correlation between PD-L1 expression and Kadish stage or Hyams grade.

Conclusion These expression data suggest that a significant number of ENBs express PD-L1 and have an associated infiltrate of CD8+ cells. Future studies are necessary to assess the potential for effectiveness of PD-L1/PD-1 inhibitors in ENB.


No conflict of interest has been declared by the author(s).

Publication History

Publication Date:
02 February 2018 (online)

© 2018. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany